READING, Mass., December 11, 2023 (Newswire.com) - Reading Dental Associates is now offering sleep apnea treatments that can help patients get a better night's sleep. Dr. Maryam Hojjati, a General Dentist at Reading Dental Associates, provides patients with a comprehensive dental exam and treatment recommendations that can help with sleep apnea. Sleep apnea affects millions of Americans from all walks of life. Left untreated, Sleep Apnea can increase a person's risk of high blood pressure, heart disease and stroke. For more information, please visit https://www.readingdentalma.com.

According to medical research, sleep conditions such as sleep apnea, snoring, insomnia, and other sleep disorders affect roughly 90 million people in North America. Obstructive sleep apnea occurs when the airways collapse or become obstructed during sleep. Patients may struggle to breathe as their oxygen levels drop. Symptoms can include loud snoring, and choking gasping. Symptoms during the day can include unexplained sleepiness or fatigue, dry mouth, sore throat and depression.

There are three major treatment options for the disorder: oral surgery; a CPAP device; and an oral appliance. Patients with severe cases of sleep apnea can elect to have invasive oral surgery by an oral surgeon if other treatment options are unsuccessful. A CPAP (Continuous Positive Airway Pressure) device is the most common treatment for moderate to severe levels of the disorder. However, a simple solution would be an oral appliance which is made to fit easily in a patient's mouth, and is often a comfortable solution for individuals with the condition. 

About Reading Dental Associates

Reading Dental Associates is a multi speciality dental clinic located in Reading Massachusetts. The practice provides multi disciplinary services including General, Cosmetic, Implant and Sedation dentistry services. The practice is dedicated to comfort and prompt attention while creating beautiful smiles and building lasting relationships with their patients. The practice delivers comprehensive and convenient dental care for your entire family and is located in Reading, MA. www.readingdentalma.com.

Precede logo

NEW CITY, N.Y., December 8, 2023 (Newswire.com) - The Pancreatic Cancer Early Detection (PRECEDE) Consortium, a beacon of hope in the global fight against pancreatic cancer, hosted its fifth annual meeting at the Cornell Tech Verizon Center on Roosevelt Island. This significant event, which took place on December 6th and 7th, marked a critical juncture in PRECEDE's mission to dramatically improve pancreatic cancer survival rates through early detection and prevention.

Pancreatic cancer, known for its low survival rate and rapid progression, has long cast a shadow over countless lives. The five-year survival rate stands at a mere 12%. PRECEDE, with its groundbreaking approach and international collaboration, aims to revolutionize this statistic, targeting an ambitious increase to 50% within the next decade.

Over 50 leading academic medical centers from around the globe highlight PRECEDE's remarkable growth and unwavering commitment. The consortium has now assembled the largest cohort of high-risk patients, supported by an unprecedented collection of longitudinal clinical data and biospecimens. This collaborative effort is not just a scientific endeavor; it's a lifeline to millions at risk of this devastating disease.

"Early detection of pancreatic cancer is not just a medical challenge; it's a promise of life," said Diane Simeone, MD, Chair, at PRECEDE. "Our collaborative model, focusing on risk modeling, screening, and prevention, particularly for those with heritable risks, is a game-changer. We are not just conducting research; we are saving lives."

Families and communities worldwide have felt the heart-wrenching impact of a disease that offers little warning and fewer options for treatment. PRECEDE's work is a beacon of hope, shining a light on the possibility of a future where this cancer can be detected early and managed effectively.

As PRECEDE entered its fifth year, the consortium is witnessing exponential growth, both in its research capabilities and its potential to make a tangible difference. The collaboration, data sharing, and innovative approaches discussed and developed at the meeting are expected to usher in a new era in the fight against pancreatic cancer.

The PRECEDE Consortium's work is a testament to the power of unity in the face of adversity. By bringing together the brightest minds and the most advanced resources, PRECEDE stands at the forefront of a movement that is not just about scientific discovery, but about giving patients and families hope, time, and a fighting chance against pancreatic cancer.

For more information about PRECEDE and its mission, please visit precedestudy.org

Supporting this critical research is Trovanow, a dedicated non-profit charity. Trovanow plays a vital role in funding and facilitating the groundbreaking work undertaken by PRECEDE. Contributions to Trovanow directly bolster the efforts to transform pancreatic cancer from a deadly disease to a manageable condition. Join this noble cause, visit trovanow.org and help support our efforts in making a significant difference in the lives of those affected by pancreatic cancer.

Precede logo

Trovanow

PARAMUS, N.J., December 7, 2023 (Newswire.com) - Advanced Data Systems RCM (ADSRCM) presented its solutions at the 2023 AMP conference in Salt Lake City for maximizing laboratory revenue while helping laboratories operate more efficiently. 

David Barzillai, President of ADSRCM, said, “Laboratorians overviewed our AI-driven platforms to (1) optimize their insurance claims, (2) capture patient responsibility balances, and (3) streamline their operations with outsourced workforce routines while empowering their sales teams to be more self-sufficient with our built-in laboratory sales portal.”  

Mr. Barzillai added, “Genetic laboratories that also perform NGS testing and laboratories in any specialty leverage our behind-the-scenes workforce as an extension of their own teams to consolidate and offload many in-laboratory routines. Laboratory clients have access to a patient responsibility estimator and an interactive balance-due texting option with online payments, which are powerful features for capturing patients’ payments. And laboratory patients contact ADSRCM if they have questions about their statements.” 

Laboratory clients have full, no-cost, transparent access to MedicsPremier, the financial and management AI-driven platform ADSRCM uses. Clients can compile reports, analytics, dashboards, and KPIs at any time, in addition to those generated by the ADSRCM team, which are routinely reviewed with clients. 

The same MedicsPremier financial/operational platform is available from Advanced Data Systems (ADS) as an in-laboratory system if preferred. 

ADSRCM and ADS interface with virtually any LIS, LIMS, G/L, EHR, and HIS. An accurate insurance discovery option to identify coverage when insurance information is missing, and an on-demand sales portal that enables a laboratory’s sales team to access needed information without disrupting other laboratory staff are also supported by ADSRCM and ADS.

Mr. Barzillai noted, “Meeting with so many AMP attendees, several of whom were ADSRCM and ADS clients, was very much appreciated. Driving clients’ revenue and efficiency is their expectation and our mission. We take pride in continually accomplishing both.”  

Contact us at 800-899-4237, Ext. 2264 or email [email protected] for more about ADSRCM, ADS, or both if comparisons for your laboratory are needed.  

SAN FRANCISCO, December 7, 2023 (Newswire.com) - Applied Research Works, Inc. (ARW), a leading provider of health data analytics and solutions, is proud to announce that its flagship product, Cozeva, has successfully passed the National Committee for Quality Assurance's (NCQA) Data Aggregator Validation (DAV) program. This significant milestone includes the exciting addition of Cozeva User Interface Entered + Enhanced Natural Language Processing (NLP) and FHIR output, marking a transformative step in healthcare data management and quality reporting.

Historically, the period between January and mid-February has been a frantic time for supplemental data submission as it was considered "non-standard". Now and in the future, Cozeva's data is recognized as "standard" after successful data validation, extending the data collection timeline to May, collectively, a game-changing advantage for healthcare providers and payers.

Top DAV Validation Impacts:

1. Meaningful Improvements in HEDIS MY2023: Significant improvements in quality measures like blood pressure, diabetes control, and more.
2. Reduced Chart Chase Burden for Payers: The DAV certification significantly decreases the need for payers to engage in time-consuming chart chases.
3. Increased Provider Participation: This validation opens doors for greater provider confidence in data and participation to close care gaps.
4. High Data Value: Shifting the expectation of the healthcare ecosystem of paying for transactional data management to actual validated data that tracks directly to performance improvement. 

"The DAV certification process allows our customers to bypass the costly and time-intensive Primary Source Verification (PSV) step. By integrating Cozeva's Provider Portal Data and leveraging our advanced NLP for data validation, customers can efficiently gather clinical information, even from providers who cannot send data electronically, and provides a level of quality oversight that promotes confidence that their clinical efforts translate into credit in their measure performance." -- Alan Chuang, SVP of Customer Success.

A study by Sarawathula et al. (2023) in the Journal of the American Medical Association highlights the immense effort and cost involved in quality metric reporting, with a large academic medical center spending over 108,478 person-hours annually, primarily on data collection and validation. Cozeva's suite of solutions is designed to reduce these burdensome manual processes significantly.

By participating in the NCQA DAV program, ARW aims to alleviate the strain of HEDIS annual reporting for health systems and requestor partners. "NCQA's DAV program has shifted the burden of Primary Source Verification onto the data vendor, removing a significant stress factor for us," stated a large national health plan representative.

Cozeva's achievement in the NCQA DAV program is a testament to ARW's commitment to pioneering healthcare data management and quality reporting solutions for our customers.

About Applied Research Works, Inc:

Applied Research Works, Inc. (ARW) is a leading health information technology and analytics company offering solutions that transform data into actionable insights. Cozeva, its flagship product, is at the forefront of advancing healthcare quality and efficiency through innovative technology. Explore more at www.cozeva.com.